Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid–Producing Microbiota in the Gut
The DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Recent studies suggest the beneficial effects of metformin on glucose metabolism may be microbially mediated. We examined the association of type 2 diabetes, metformin, and gut microbiota in community-dwelling Colombian adults. On the basis of previous research, we hypothesized that metformin is associated with higher levels of short-chain fatty acid (SCFA)–producing and mucin-degrading microbiota. RESEARCH DESIGN AND METHODS: Participants were selected from a larger cohort of 459 participants. The present analyses focus on the 28 participants diagnosed with diabetes—14 taking metformin— and the 84 participants without diabetes who were matched (3-to-1) to participants with diabetes by sex, age, and BMI. We measured demographic information, anthropometry, and blood biochemical parameters and collected fecal samples from which we performed 16S rRNA gene sequencing to analyze the composition and structure of the gut microbiota. RESULTS: We found an association between diabetes and gut microbiota that was modified by metformin use. Compared with participants without diabetes, participants with diabetes taking metformin had higher relative abundance of Akkermansia muciniphila, a microbiota known for mucin degradation, and several gut microbiota known for production of SCFAs, including Butyrivibrio, Bifidobacterium bifidum, Megasphaera, and an operational taxonomic unit of Prevotella. In contrast, compared with participants without diabetes, participants with diabetes not taking metformin had higher relative abundance of Clostridiaceae 02d06 and a distinct operational taxonomic unit of Prevotella and a lower abundance of Enterococcus casseliflavus. CONCLUSIONS: Our results support the hypothesis that metformin shifts gut microbiota composition through the enrichment of mucin-degrading A. muciniphila as well as several SCFA-producing microbiota. Future studies are needed to determine if these shifts mediate metformin’s glycemic and anti-inflammatory properties.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Biguanides/metformin, the first-line therapeutics for T2D, modifies microbiota leading to an increase in A. muciniphila, as well as several SCFA-producing microbiota, favoring an improvement on mucin-producing goblet cells, pro-inflammatory IL-6, and glucose tolerance [304].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [304]
In the citing paper
“In human diabetic individuals, metformin was shown to shift gut microbiota composition to predominantly short-chain fatty-acid producing microbes”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as de la Cuesta-Zuluaga et al. 2017
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192 · cited 2×
“pairwise tests among groups of participants using the unpaired Wilcoxon rank sum test, and finally uses LDA to estimate the effect size of each differentially abundant OTU (24).”
MethodKozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K., & Schloss, P. D. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.01043-13 · Cited by 7,112
A metagenome-wide association study of gut microbiota in type 2 diabetes
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., et al. (2012) · Nature · doi:10.1038/nature11450 · Cited by 6,762 · cited 1×
“Given the considerable variation in the microbiota associated with type 2 diabetes and that the gut microbiota of Colombians is different to that of other populations (18), we hypothesized that the microbial taxa involved in the type 2 diabetes dysbiosis of Colombians are different to those observed in Chinese and Eur…”
BackgroundLinking long-term dietary patterns with gut microbial enterotypes
Wu, G. D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.-Y., Keilbaugh, S. A., Bewtra, M., Knights, D., Walters, W. A., Knight, R., et al. (2011) · Science · doi:10.1126/science.1208344 · Cited by 6,513 · cited 1×
“Prevotella has been associated with carbohydrate-baseddiets anddegradation of complex polysaccharides (26), whereas E.”
BackgroundCross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity
Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., Guiot, Y., Derrien, M., Muccioli, G. G., Delzenne, N. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219451110 · Cited by 4,511 · cited 3×
“abundance of Akkermansia muciniphila (11–13), a mucin-degrading bacteria that has been shown to reverse metabolic disorders (1,12).”
BackgroundInfluentialGut metagenome in European women with normal, impaired and diabetic glucose control
Karlsson, F. H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C. J., Fagerberg, B., Nielsen, J., & Bäckhed, F. (2013) · Nature · doi:10.1038/nature12198 · Cited by 3,115 · cited 1×
“Given the considerable variation in the microbiota associated with type 2 diabetes and that the gut microbiota of Colombians is different to that of other populations (18), we hypothesized that the microbial taxa involved in the type 2 diabetes dysbiosis of Colombians are different to those observed in Chinese and Eur…”
BackgroundGut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults
Larsen, N., Vogensen, F. K., van den Berg, F. W. J., Nielsen, D. S., Andreasen, A. S., Pedersen, B. K., Al-Soud, W. A., Sørensen, S. J., Hansen, L. H., & Jakobsen, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009085 · Cited by 2,952
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
Wahlström, A., Sayin, S. I., Marschall, H.-U., & Bäckhed, F. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.005 · Cited by 2,851 · cited 1×
“through effects on bile acid secretion (31).”
Review article: the role of butyrate on colonic function
HAMER, H. M., JONKERS, D., VENEMA, K., VANHOUTVIN, S., TROOST, F. J., & BRUMMER, R. ‐. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03562.x · Cited by 2,721 · cited 1×
“Butyrate, in particular, is one of the preferred energy sources of the colonic epithelium (36).”
BackgroundBifidobacteria can protect from enteropathogenic infection through production of acetate
Fukuda, S., Toh, H., Hase, K., Oshima, K., Nakanishi, Y., Yoshimura, K., Tobe, T., Clarke, J. M., Topping, D. L., Suzuki, T., et al. (2011) · Nature · doi:10.1038/nature09646 · Cited by 2,387 · cited 1×
“Acetate produced by bifidobacteria improves the intestinal defense mediated by epithelial cells and protects thehost against lethal infection (34).”
BackgroundMicrobiota-Generated Metabolites Promote Metabolic Benefits via Gut-Brain Neural Circuits
De Vadder, F., Kovatcheva-Datchary, P., Goncalves, D., Vinera, J., Zitoun, C., Duchampt, A., Bäckhed, F., & Mithieux, G. (2014) · Cell · doi:10.1016/j.cell.2013.12.016 · Cited by 2,200
Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., et al. (2015) · Nature · doi:10.1038/nature15766 · Cited by 2,116 · cited 9×
“In contrast, four OTUs of Clostridiales including Clostridium celatum (Firmicutes| Clostridiaceae|OTU014), Clostridiaceae SMB53 (Firmicutes|Clostridiaceae| OTU026), Oscillospira (Firmicutes| Ruminococcaceae|OTU024), and Cellulosibacter alkalithermophilus (Firmicutes| Ruminococcaceae|OTU025) were more abundant in ND th…”
InfluentialMachiels, K., Joossens, M., Sabino, J., De Preter, V., Arijs, I., Eeckhaut, V., Ballet, V., Claes, K., Van Immerseel, F., Verbeke, K., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-304833 · Cited by 1,904 · cited 1×
“, inflammatory bowel disease), highlighting the role of SCFAs in disease resistance (39,40).”
BackgroundKelly, C. J., Zheng, L., Campbell, E. L., Saeedi, B., Scholz, C. C., Bayless, A. J., Wilson, K. E., Glover, L. E., Kominsky, D. J., Magnuson, A., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.03.005 · Cited by 1,716 · cited 1×
“epithelial metabolism and deplete intracellular O2, resulting in stabilization of the transcription factor HIF-1 and increasing epithelial barrier function (38).”
BackgroundShin, N.-R., Lee, J.-C., Lee, H.-Y., Kim, M.-S., Whon, T. W., Lee, M.-S., & Bae, J.-W. (2014) · Gut · doi:10.1136/gutjnl-2012-303839 · Cited by 1,550
Metformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,349 · cited 1×
“Metformin (1,1-dimethylbiguanide hydrochloride) is the most frequent medication used to treat type 2 diabetes (7), and findings from recent studies suggest it may also prevent cancer (7) and cardiovascular events (8).”
BackgroundLow counts of Faecalibacterium prausnitzii in colitis microbiota
Sokol, H., Seksik, P., Furet, J. P., Firmesse, O., Nion-Larmurier, I., Beaugerie, L., Cosnes, J., Corthier, G., Marteau, P., & Doré, J. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20903 · Cited by 1,275 · cited 1×
“, inflammatory bowel disease), highlighting the role of SCFAs in disease resistance (39,40).”
BackgroundAssociating microbiome composition with environmental covariates using generalized UniFrac distances
Chen, J., Bittinger, K., Charlson, E. S., Hoffmann, C., Lewis, J., Wu, G. D., Collman, R. G., Bushman, F. D., & Li, H. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts342 · Cited by 1,145 · cited 1×
“latedwith theGUniFrac package of R (23).”
Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism
Cabreiro, F., Au, C., Leung, K.-Y., Vergara-Irigaray, N., Cochemé, H. M., Noori, T., Weinkove, D., Schuster, E., Greene, N. D. E., & Gems, D. (2013) · Cell · doi:10.1016/j.cell.2013.02.035 · Cited by 967 · cited 1×
“(28) first demonstrated that metformin impacts the”
Human Gut Microbiota Changes Reveal the Progression of Glucose Intolerance
Zhang, X., Shen, D., Fang, Z., Jie, Z., Qiu, X., Zhang, C., Chen, Y., & Ji, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071108 · Cited by 946
Vancomycin-Resistant Enterococcal Infections
Murray, B. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003093421007 · Cited by 890 · cited 1×
“casseliflavus is an opportunistic pathogen that may cause serious infections in immunosuppressed individuals (27).”
BackgroundZhang, X., Zhao, Y., Xu, J., Xue, Z., Zhang, M., Pang, X., Zhang, X., & Zhao, L. (2015) · Scientific Reports · doi:10.1038/srep14405 · Cited by 630 · cited 1×
“Recent studies in animals (11,12,13) and humans (6,17) provide evidence that metformin may partially restore gut dysbiosis associated with type 2 diabetes.”
BackgroundMolecular mechanism of action of metformin: old or new insights?
Rena, G., Pearson, E. R., & Sakamoto, K. (2013) · Diabetologia · doi:10.1007/s00125-013-2991-0 · Cited by 479
Effect of Metformin on Metabolic Improvement and Gut Microbiota
Lee, H., & Ko, G. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.01357-14 · Cited by 385 · cited 1×
“Recent studies in animals (11,12,13) and humans (6,17) provide evidence that metformin may partially restore gut dysbiosis associated with type 2 diabetes.”
BackgroundLamanna, C., Monami, M., Marchionni, N., & Mannucci, E. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01349.x · Cited by 364 · cited 1×
“Metformin (1,1-dimethylbiguanide hydrochloride) is the most frequent medication used to treat type 2 diabetes (7), and findings from recent studies suggest it may also prevent cancer (7) and cardiovascular events (8).”
BackgroundTurroni, F., Bottacini, F., Foroni, E., Mulder, I., Kim, J.-H., Zomer, A., Sánchez, B., Bidossi, A., Ferrarini, A., Giubellini, V., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011100107 · Cited by 364
Buse, J. B., DeFronzo, R. A., Rosenstock, J., Kim, T., Burns, C., Skare, S., Baron, A., & Fineman, M. (2016) · Diabetes Care · doi:10.2337/dc15-0488 · Cited by 325 · cited 1×
“effect than immediate-release or extendedrelease metformin, despite the delayedreleasemetformin having lower systemic exposure than the other metformin formulations (15).”
BackgroundMannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Messeri, G., & Rotella, C. M. (2001) · Diabetes Care · doi:10.2337/diacare.24.3.489 · Cited by 300 · cited 1×
“Metformin has also been shown to enhance active and total glucagon-like peptide 1 (17,29,30), which is consistent with the hypothesis that it increases SCFA production through modification of the gut microbiota composition.”
BackgroundMaida, A., Lamont, B. J., Cao, X., & Drucker, D. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1937-z · Cited by 294
Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus
Napolitano, A., Miller, S., Nicholls, A. W., Baker, D., Van Horn, S., Thomas, E., Rajpal, D., Spivak, A., Brown, J. R., & Nunez, D. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100778 · Cited by 282
Repurposing metformin: an old drug with new tricks in its binding pockets
Pryor, R., & Cabreiro, F. (2015) · Biochemical Journal · doi:10.1042/bj20150497 · Cited by 280
Bailey, C. J., Wilcock, C., & Scarpello, J. H. B. (2008) · Diabetologia · doi:10.1007/s00125-008-1053-5 · Cited by 275 · cited 1×
“Metformin is ;50% bioavailable, allowing for near-equal intestinal and plasma exposure, but intestinal accumulation of metformin is 300 times that of the plasma (16), making the gut the primary reservoir for metformin in humans.”
BackgroundThe gut microbiota of Colombians differs from that of Americans, Europeans and Asians
Escobar, J. S., Klotz, B., Valdes, B. E., & Agudelo, G. M. (2014) · BMC Microbiology · doi:10.1186/s12866-014-0311-6 · Cited by 227 · cited 1×
“Given the considerable variation in the microbiota associated with type 2 diabetes and that the gut microbiota of Colombians is different to that of other populations (18), we hypothesized that the microbial taxa involved in the type 2 diabetes dysbiosis of Colombians are different to those observed in Chinese and Eur…”
BackgroundSelf-citationSutterella parvirubra sp. nov. and Megamonas funiformis sp. nov., isolated from human faeces
Sakon, H., Nagai, F., Morotomi, M., & Tanaka, R. (2008) · INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY · doi:10.1099/ijs.0.65456-0 · Cited by 166
Bonora, E., CIGOLINI, M., Bosello, O., Zancanaro, C., Capretti, L., Zavaroni, I., Coscelli, C., & BUTTURINI, U. (1984) · Current Medical Research and Opinion · doi:10.1185/03007998409109558 · Cited by 85 · cited 1×
“Unlike oral administration, intravenous administration of metformin in humans does not improve glycemia (14).”
BackgroundGargari, G., Taverniti, V., Balzaretti, S., Ferrario, C., Gardana, C., Simonetti, P., & Guglielmetti, S. (2016) · Applied and Environmental Microbiology · doi:10.1128/aem.01753-16 · Cited by 85
Cited by
Gut microbiota in human metabolic health and disease
Fan, Y., & Pedersen, O. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0433-9 · Cited by 4,724
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01251-0 · Cited by 1,718
You are what you eat: Diet, health and the gut microbiota
Zmora, N., Suez, J., & Elinav, E. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0061-2 · Cited by 1,792
Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L. M., Serino, M., Planas-Fèlix, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4345 · Cited by 1,632
Human gut microbiome: Hopes, threats and promises
Cani, P. D. (2018) · Gut · doi:10.1136/gutjnl-2018-316723 · Cited by 1,386
Metadata
- Authors
- de la Cuesta-Zuluaga, J., Mueller, N. T., Corrales-Agudelo, V., Velásquez-Mejía, E. P., Carmona, J. A., Abad, J. M., & Escobar, J. S.
- Affiliations
- Vidarium—Nutrition, Health and Wellness Research Center, Grupo Empresarial Nutresa, Medellin, Colombia
- Johns Hopkins University (US)
- Vidarium - Centro de Investigación en Nutrición Salud y Bienestar (CO)
- Dinámica I.P.S.—Especialista en Ayudas Diagnósticas, Medellin, Colombia
- EPS y Medicina Prepagada Suramericana S.A., Medellin, Colombia
- Corresponding author
- Escobar, Juan S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-11-14
- Volume
- 40
- Issue
- 1
- Pages
- 54-62
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2553515186
- Cited by
- 704
- References
- 40
- Citations by year
- 2026: 55 · 2025: 69 · 2024: 86 · 2023: 80 · 2022: 106 · 2021: 78 · 2020: 87 · 2019: 62 · 2018: 45 · 2017: 33 · 2016: 1
- FWCI
- 24.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- metformin, Akkermansia muciniphila, gut microbiota, short-chain fatty acids, type 2 diabetes, mucin degradation, Butyrivibrio, Bifidobacterium bifidum, Megasphaera, Prevotella, Clostridiaceae, Enterococcus casseliflavus, fecal microbiota composition, glycemic control
- MeSH terms
- Gastrointestinal Microbiome, Adolescent, Adult, Colombia, Diabetes Mellitus, Type 2, Fatty Acids, Volatile, Feces, Female, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Mucins, RNA, Ribosomal, 16S, Case-Control Studies, Verrucomicrobia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.